(Q35190088)

7 August 2017

1 reference

title

Current systemic therapies for psoriasis: where are we now? (English)

1 reference

7 August 2017

Paul S Yamauchi

1

1 reference

7 August 2017

Dalia Rizk

2

1 reference

7 August 2017

Tanya Kormeili

3

1 reference

7 August 2017

Rickie Patnaik

4

1 reference

7 August 2017

Nicholas J Lowe

5

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Journal of the American Academy of Dermatology

7 August 2017

1 reference

7 August 2017

49

1 reference

7 August 2017

S66-77

1 reference

7 August 2017

2 Suppl

1 reference

Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVA and methotrexate therapy

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Aminopterin for psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Treatment of psoriasis with folic acid antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Methotrexate in psoriasis: consensus conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Methotrexate for psoriasis. A new therapeutic schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

[Reactivation of sunburn by methotrexate]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Pancytopenia following low-dose oral methotrexate therapy for psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Methotrexate and histologic hepatic abnormalities: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Cyclosporine in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Treatment of resistant severe psoriasis with systemic cyclosporine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Cyclosporine as maintenance therapy in patients with severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Low dose cyclosporin A treatment in generalized pustular psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Posttransplant lymphoproliferative disorder in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Systemic retinoid therapy for psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Acitretin: optimal dosing strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Acitretin in combination with UVB or PUVA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Calcipotriol ointment. A review of its use in the management of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Treatment of psoriasis. Part 2. Systemic therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Treatment Of Psoriasis With Oral Mycophenolic Acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Hydroxyurea: a new antimetabolite in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Hydroxyurea in the management of therapy resistant psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Rediscovering hydroxyurea: its role in recalcitrant psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

6-Thioguanine treatment of psoriasis: experience in 81 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Pulse dosing of thioguanine in recalcitrant psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Thioguanine for refractory psoriasis: a 4-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Sulphasalazine in the management of psoriatic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Sulfasalazine: a potential psoriasis therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Azathioprine: a forgotten alternative for treatment of severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

Study of psoriatic epidermal cell kinetics and cell death after oral methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunity during cyclosporine therapy

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

inferred from DOI database lookup

7 January 2021

based on heuristic

Mycophenolic acid in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FMJD.2003.550

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/MJD.2003.550

1 reference

7 August 2017

1 reference